While hi-tech hospitals and other medical facilities become your prime concern, at the

time of any medical emergency, there is hardly any thought given to the backbone of the

medical industry – the diagnostic companies.

They work silently in tandem with hospitals and develop new technologies that are easing

the work for pathologists and diagnostic centers at large.

One such company is Applied BioCode, which is slowly and steadily making its mark in

the diagnostic industry.

With a complete focus on research and development, manufacturing, and

commercialization of assay testing kits, Applied BioCode, additionally deals in

instruments for in-vitro diagnostics, research, and other industrial applications.

"Applied BioCode is an in-vitro diagnostics manufacturer. We not only design, develop,

but also commercialize multiplex testing products. The company has combined 'digital

barcodes' with immuno- and molecular chemistry to create a new, bio-inspired

Barcoded Magnetic Beads (BMB) technology." Said Chris Bernard, CEO, Applied

BioCode

Talking about the micro BMBs, Chris Bernard said they are about the diameter of human

hair and are tagged with immunochemistry or molecular probes. Thus, facilitating

scanning and accurate identification of these probes up to 4,096 barcodes with no

ambiguous biological targets.

Applied BioCode's cost-effective technology addresses challenges associated with

developing syndromic panels. "We are an ideal cost-ef ective partner for new and existing

high volume, diagnostic labs: Via high throughput capabilities and ability to run dif erent

types of panels concurrently," added Chris Bernard.

Applied BioCode has an exclusive partnership and an agreement with IDEXX and an

exclusive distribution agreement with Hardy Diagnostics – a leader in the microbiology

space that enabled Applied BioCode to access hospital accounts and enabled Hardy to

penetrate the Molecular Dx space.

There will be numerous trends that will impact Molecular Diagnostics in 2022. However,

Chris Bernard listed some prominent trends and how Applied BioCode plans to leverage

those trends and evolve.

• There has been an increasing incidence of chronic and infectious diseases and the

evolving awareness about the early diagnosis of diseases.

• Automation plays an important role in system and menu consolidation.

• With the enhanced ability to select individual targets, a movement was created toward

multiplexed syndromic test panels.

• MolDx technical assessments of LDTs are believed to steer labs to adopt IVD assays vs.

developing LDTs.

Speaking about the challenges in the Molecular Diagnostics space and how Applied

BioCode addresses those issues, Chris Bernard said, " Applied BioCode is able to deliver

precisely what the customer is looking for via our masking solution. It complements our

super competitive pricing and system flexibility. [D1]The MDX-3000 can truly position

the hospital labs as a profit center vs. a cost center and provide the private labs an

opportunity to dif erentiate themselves in the marketplace."

With the tagline 'We offer Flexible and Cost-Effective Syndromic Testing,' Applied

BioCode aims to portray the features of its product BioCode® MDx-3000. As Chris

Bernard said, "The BioCode® MDx-3000 is an easy-to-use, cost-ef ective automated

molecular diagnostic system that integrates the post-extraction processes of molecular

diagnostic testing. The BioCode® MDx-3000 system automates the PCR amplification,

hybridization/target capture, and detection steps of molecular testing. Automation, along

with a simplified workflow, reduces hands-on time for labor savings and minimizes the

potential for sample contamination."

When clients talk about the product, you know you are on the right track. And this is what

Dr. Anami Patel of Popular Healthcare – one of the clients of Applied BioCode – said

about the product.

"At Poplar Healthcare, our goal is to positively impact the diagnostic testing process to

pass on those benefits to our patients. We have done this by optimizing operational

efficiency and effectiveness while practicing Lean management principles. Adopting the

Applied BioCode platform, namely the BioCode® Gastrointestinal Pathogen Panel on the

BioCode® MDx-3000 Instrument, has improved our lab workflow, where we receive

accurate and fast test results while experiencing reduced invalid rates in our data. It, in

turn, has enabled clinicians to manage their patients effectively."

Elaborating on the strategies employed by Applied BioCode to thwart market competition,

Chris Bernard said that certain distinct features of BioCode give it a competitive edge. The

differentiating factors of the product include-

● Ability to the multiplex in a cost-effective manner

● Masking option enabling to customize test results based on the clinician's order

● Throughput flexibility supports running three different tests in parallel, which mean

that lab are not constrained to a 96-sample system.

● The simplified workflow reduces hands-on time, which translates to labor

savings and minimizes the potential for sample contamination.

Speaking about the future, Chris Bernard said, "We are actively assessing multiple

strategies and markets and exploring partnerships in the US and OUS. With ABC's listing

on the Taiwanese stock exchange and our strong capital position, we will be aggressive

with brand awareness strategy and product pipeline."

But the future without some history is meaningless. History has it that Dr. Winston Z

Ho, President of Applied BioCode, designed advanced biomolecular testing systems with

Maxwell Sensors – the biomedical research and development company founded in 1998.

And by 2008, Maxwell Sensors was ready to commercialize its BMB technology in the

diagnostics space, giving birth to Applied BioCode, Inc.